Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Similar documents
Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie

Financial disclosures

Klinisch belang van chromosomale translocatie detectie in sarcomen

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement

Surgical Pathology Evening Specialty Conference USCAP 2015

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA

Financial disclosures

Disclosure of Relevant Financial Relationships

Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls

Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology

Recent Advances In Select Round Cell Sarcomas

Enterprise Interest Nothing to declare

HOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE?

Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist

3/27/2017. Disclosure of Relevant Financial Relationships

Slide Seminar Spanish Society of Pathology

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology

USCAP COMPANION MEETING INTERNATIONAL SOCIETY OF BONE AND SOFT TISSUE PATHOLOGY DENVER, March 2 nd 2008

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review. Munir R. Tanas, MD and John R.

Disclosure of Relevant Financial Relationships

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

Diagnostic Approach to Soft Tissue Tumors

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Evening Specialty Conference Bone and Soft Tissue Pathology. Diagnostic pitfalls in bone and soft tissue pathology

Lung Tumor Cases: Common Problems and Helpful Hints

Newer soft tissue entities

Case Presentations 17-20

IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS

ASCP Resident Review Mini-Course Series Session 2: Renal and Soft Tissue Pathology. Carole Vogler MD, FASCP Ema Dragoescu MD

Rhabdomyomas and Rhabdomyosarcomas (RMS) David M. Parham, MD Chief of Anatomic Pathology

Mayo Medical Laboratories

The last 10 years have seen the description of many

ACCME/Disclosures. Everything is spindle - how far can we go with limited FNA material? Everything is spindle how far can we go? Everything is spindle

5/10. Pathology Soft tissue tumors. Farah Bhani. Mohammed Alorjani

Keywords solitary fibrous tumor, dedifferentiation, dedifferentiated solitary fibrous tumor, STAT6, GRIA2, cytokeratin, rhabdomyosarcomatous

Shintaro Sugita *, Hiroko Asanuma and Tadashi Hasegawa

Protocol for the Examination of Biopsy Specimens From Pediatric Patients With Ewing Sarcoma

Index. J Juvenile hyaline fibromatosis, 27 Juvenile xanthogranuloma, 57 Juxta-articular myxoma, 152

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Conceptual Evolution of Soft Tissue Tumors Classification

SOFT TISSUE TUMOR PATHOLOGY: AN UPDATE

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Clinical History. Pediatric Tumors with Involvement of the Head & Neck

Financial disclosures

INDEX. in this web service Cambridge University Press

57th Annual HSCP Spring Symposium 4/16/2016

Part 1. Slides 1-38, Rita Alaggio Soft tissue tumors Trondheim 14. mars 2013

Molecular pathology/genetics of sarcomas

Pediatric Soft Tissue Tumors

Case 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors

Best of ASCO 2014 Sarcoma

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Enterprise Interest None

Original Articles. Utilization of Fluorescence In Situ Hybridization in the Diagnosis of 230 Mesenchymal Neoplasms. An Institutional Experience

Mimics of Sarcoma. I have no conflict of interest to declare

Update on Cutaneous Mesenchymal Tumors. Thomas Brenn

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Khin Thway, Jayson Wang, Taka Mubako, and Cyril Fisher. 1. Introduction

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Mesothelioma Pathobasic. Lukas Bubendorf Pathology

The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors

The Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone

Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat version (downloaded 3/23/2017)

I sarcomi dei tessuti molli

S2199 S2200. * Speaker's diagnosis 78

Diagnostic Value of Immunohistochemistry in Soft Tissue Tumors

Salivary Gland FNA ATYPICAL : Criteria and Controversies

Introduction to Musculoskeletal Tumors. James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon

Biopsy Interpretation of Spindle cell proliferations of the Serosa

A 25 year old female with a palpable mass in the right lower quadrant of her abdomen

PROBLEMS OF PROGNOSTICATION IN SOFT TISSUE TUMOURS. Christopher D.M. Fletcher Brigham and Women s Hospital and Harvard Medical School Boston, MA

USCAP Pediatrics Evening Subspecialty Conference 2015

Small Round Cell Tumors in Soft Tissue and Bone. ACCME/Disclosure. Adult Small Round Cell Tumors. Ewing Sarcoma 4/13/2016

Aspen conference on pediatric disease. July through August Bone and Soft Tissue Update. David M. Parham, MD. Rhabdomyoma and rhabdomyosarcoma

1/10/2018. Soft Tissue Tumors Showing Melanocytic Differentiation. Overview. Desmoplastic/ Spindle Cell Melanoma

Journal of Solid Tumors, April 2012, Vol. 2, No. 2

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.

Cheryl M. Coffin, M.D. Goodpasture Professor of Pathology, Microbiology, and Immunology Vanderbilt University Nashville, TN, USA

Case 1 10/2/17. Myxoid Soft Tissue Tumors & Tumor-like Lesions. Myxofibro- or Fibromyxo-?: Myxoid Soft Tissue Tumours We Are All Mixed Up About

Notice of Faculty Disclosure

ESS: Pathologic Insights

Recommendations for Reporting Soft Tissue Sarcomas

ACCME/Disclosures ALK FUSION-POSITIVE MESENCHYMAL TUMORS. Tumor types with ALK rearrangements. Anaplastic Lymphoma Kinase. Jason L.

La chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms

An Overview of Genital Stromal Tumors

Gene Translocations in Musculoskeletal Neoplasms

Soft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement

* I have no disclosures or any

The Completeness of Soft Tissue Sarcoma Data in the National Cancer Data Repository

Difficult Diagnoses and Controversial Entities in Neoplastic Lung

Technology from Abcam

Application of Whole Genome Microarrays in Cancer: You should be doing this test!!

Transcription:

Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques Bone and soft tissue tumors are rare (<1 % of neoplasms) >100 unique soft tissue diagnoses in WHO 2013 Goal of diagnosis: reproducible classification of lesions with differing clinical behavior and prognosis H&E might not be enough Sensitivity: smaller biopsies Specificity: overlapping histologic features Immunohistochemistry Lineage specific Indicators of genetic and molecular abnormalities Molecular and Genetic testing Available techniques Advantages and Limitations Selected examples 1

Immunohistochemistry (IHC) 1. Lineage specific proteins 2. Indicators of genetic and molecular abnormalities (amplifications, deletions, translocations, point mutations) IHC: Lineage specific proteins Classic approach Cytoplasmic: Desmin, keratin, actins, S-100, CD34, CD31 Nuclear transcription factors Skeletal muscle: Myogenin Neural crest: SOX10 Others: SOX9, ERG, SATB2 Gene expression profiling MUC4 Others: DOG1, TLE1 Myogenin Alveolar RMS Myogenin Embryonal RMS Master regulator of skeletal muscle differentiation ~100% specific (myf4 monoclonal) for rhabdomyoblastic differentiation Rhabdomyosarcoma (all types) Heterologous rhabdomyoblastic differentiation Triton tumor, dedifferentiated liposarcoma, myxoid liposarcoma, Wilms tumor Can help distinguish subtypes of rhabdomyosarcoma Myogenin Myogenin 2

SOX10 SOX10 SRY-related HMG box transcription factor Sensitive for neural crest-derived tumors Melanoma Schwannoma, neurofibroma (>99%) Malignant peripheral nerve sheath tumor (50%, focal) Specificity Negative in synovial sarcoma, GIST, smooth muscle Positive in astrocytomas, myoepitheliomas, breast carcinoma (10%) MPNST SOX10 Synovial sarcoma SOX10 IHC: Lineage specific proteins, gene expression profiling MUC4 Glycoprotein on glandular epithelium Highly expressed in Low-grade fibromyxoid sarcoma Hyalanizing spindle cell tumor with giant rosettes Sclerosing epithelioid fibrosarcoma t(7;16) positive Negative Perineurioma, MPNST, desmoid, myxofibrosarcoma Low-grade fibromyxoid sarcoma MUC4 MUC4 3

IHC: Indicators of genetic changes IHC: Amplification Amplification MDM2, CDK4 Chromosomal translocations STAT6 Others: FLI1, TFE3 Deletion INI1 Rb Point mutation β-catenin Others: IDH1, BRAF Liposarcoma Well-differentiated Dedifferentiated Osteosarcoma Parosteal Central low-grade MDM2 / CDK4 MDM2 / CDK4 Well-differentiated liposarcoma MDM2, CDK4 MDM2, CDK4 Parosteal osteosarcoma De-differentiated liposarcoma MDM2, CDK4 4

IHC: Chromosomal translocation STAT6 Transcription factor, moves to nucleus when activated (phosphorylated) Fusion NAB2-STAT6 in solitary fibrous tumor abnormal nuclear localization of STAT6 Sensitivity 98% Specificity >90% Dedifferentiated liposarcoma Solitary fibrous tumor STAT6 STAT6 STAT6 STAT6 Dedifferentiated liposarcoma STAT6 Dedifferentiated liposarcoma Doyle LA et al. Mod Pathol 2014; 1-7. 5

IHC: Gene deletion INI1 (SNF5/SMARCB1) Chromatin remodeling, tumor suppressor, constitutively expressed Loss of expression Epithelioid sarcoma (gene deletion) Atypical teratoid rhabdoid tumor (inactivation) Rhabdoid tumor (inactivation) Poorly differentiated chordoma (?) INI1 (loss) Epithelioid sarcoma INI 1 INI1 (loss) IHC: Gene deletion or mutation Extrarenal rhabdoid tumor INI 1 Rb Retinoblastoma gene 13q14 Tumor suppressor Deleted or mutated Spindle cell lipoma Pleomorphic lipoma Mammary type myofibroblastoma Cellular angiofibroma Retained in Other benign and malignant lipomatous tumors Solitary fibrous tumor 24 6

Rb (complete loss) IHC: Point mutation Spindle cell lipoma Rb β-catenin Encoded by CTNNB1 gene, Wnt signaling pathway Desmoid tumor: mutations in CTNNB1 (sporadic) or APC (Gardner syndrome) abnormal localization Normal cells: membrane Scar, GIST, smooth muscle: membrane Desmoid fibromatosis: nuclear (+ cytoplasm) (70-90%) Nuclear β-catenin Desmoid fibromatosis Genetic and molecular testing Purpose Classification: Separation of tumors into clinically meaningful categories based on reproducible changes Prognostic: Alveolar versus embryonal rhabdomyosarcoma Myxoid versus well-differentiated liposarcoma Predictive: Therapeutic target from fusion gene product Techniques Cytogenetic: Karyotype, FISH Molecular: RT-PCR, Sanger sequencing, MLPA, array 7

Cytogenetics Cytogenetics: 33 year old woman, knee mass Karyotype FISH Tissue source Fresh, dividing cells FFPE, cyto smears, frozen Turnaround >1 wk ~ 1 wk Specificity Shotgun approach Directed approach Advantages Disadvantages Direct correlation between morphology and genetics Low resolution Karyotyping: Synovial sarcoma Cytogenetics: FISH t(x;18) Source: National human genome research institute 8

77 year old man, left femur mass, cough Small cell carcinoma FISH: Ewing sarcoma Lymphoma (DLBCL) EWSR1 rearrangement Ewing/PNET 9

EWSR1 rearrangements Molecular genetics Partner FLI1, ERG, ETV1, EIAF, FEV, others ATF1, CREB1 NR4A3 WT1 DDIT3 POU5F1 Diagnosis Ewing sarcoma family of tumors Clear cell sarcoma Angiomatoid fibrous histiocytoma Extraskeletal myxoid chondrosarcoma Desmoplastic small round cell tumor Myxoid liposarcoma Myoepithelial tumors RT-PCR Next gen sequencing Tissue source Frozen > FFPE Frozen, + normal control Turnaround < 1-2 days > 1 wk Specificity Highly directed Shotgun approach Advantages High specificity Disadvantages No correlation between morphology and genetics 43 year old woman, thigh mass Synovial sarcoma Extraskeletal myxoid chondrosarcoma SYT-SSX fusion EWSR1-NR4A3 fusion 10

PCR: translocation High throughput assays Array based sequencing Vergara-Lluir M, et al. Am J Surg Pathol 2012; 36:1093 Pavlopoulos GA, et al.. BioData Min. 2013 25;6(1):13. New markers identified by high throughput methods Genetics MYH9-USP6 NAB2-STAT6 t(1;10)(p22;q24) HEY1-NCOA2 CIC-DUX4 BCOR-CCNB3 Diagnosis Nodular fasciitis Solitary fibrous tumor Myxoinflammatory fibroblastic sarcoma Hemosiderotic fibrolipomatous tumor Mesenchymal chondrosarcoma Ewing-like sarcoma Ewing-like sarcoma 90 80 70 60 50 40 30 20 10 Molecular genetics of sarcoma 0 1960 1970 1980 1990 2000 2010 2020 Time # of tumors characterized # of genetic /molecular aberrations 11

Take-home messages Solid Tumors Test Directory Lineage-specific is a relative term IHC for nuclear transcription factors offer advantages over older cytoplasmic proteins IHC can indirectly detect tumor-specific genetic and molecular abnormalities Gene and molecular abnormalities can be detected directly by more specialized methods High throughput methods can rapidly screen an entire tumor genome and may allow personalized medicine http://www.amptestdirectory.org/directory/st_test_list.php 12